

Antonella Castagna

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6385829/antonella-castagna-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

340
papers

12,840
citations

50
h-index

106
g-index

349
ext. papers

15,061
ext. citations

6.1
avg. IF

5.83
L-index

#	Paper	IF	Citations
340	Compassionate Use of Remdesivir for Patients with Severe Covid-19. <i>New England Journal of Medicine</i> , 2020 , 382, 2327-2336	59.2	1691
339	A whole-genome association study of major determinants for host control of HIV-1. <i>Science</i> , 2007 , 317, 944-7	33.3	999
338	Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. <i>Archives of Internal Medicine</i> , 2006 , 166, 1632-41		869
337	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 1048-1057	27.4	629
336	Common genetic variation and the control of HIV-1 in humans. <i>PLoS Genetics</i> , 2009 , 5, e1000791	6	310
335	Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. <i>Lancet, The</i> , 1993 , 342, 398-401	40	277
334	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020 , 76, 43-49	3.9	270
333	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004 , 364, 51-62	40	267
332	Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. <i>Journal of Infectious Diseases</i> , 2014 , 210, 354-62	7	232
331	Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013 , 10, e1001510	11.6	212
330	All-cause mortality in treated HIV-infected adults with CD4 ≥ 500 /mm ³ compared with the general population: evidence from a large European observational cohort collaboration. <i>International Journal of Epidemiology</i> , 2012 , 41, 433-45	7.8	184
329	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. <i>Aids</i> , 2008 , 22, 2143-53	3.5	180
328	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. <i>Lancet HIV, the</i> , 2015 , 2, e98-106	7.8	172
327	Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. <i>Clinical Immunology</i> , 2020 , 217, 108509	9	167
326	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1277-1285	2.4	164
325	Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. <i>Aids</i> , 1996 , 10, 951-8	3.5	140
324	Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. <i>Aids</i> , 2011 , 25, 1385-94	3.5	139

323	Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement. <i>Annals of Neurology</i> , 1991 , 29, 21-5	9.4	131
322	CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. <i>PLoS Medicine</i> , 2012 , 9, e1001194	11.6	119
321	Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). <i>Aids</i> , 2006 , 20, 795-803	3.5	117
320	Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. <i>Journal of Infectious Diseases</i> , 2015 , 211, 178-86	7	114
319	Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. <i>Journal of Infectious Diseases</i> , 1992 , 166, 1408-11	7	113
318	Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2004 , 39, 1681-91	11.6	111
317	Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 451-457	9.5	110
316	Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. <i>Journal of Infectious Diseases</i> , 2003 , 188, 635-42	7	108
315	Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. <i>PLoS Medicine</i> , 2015 , 12, e1001809	11.6	107
314	Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1312-21	11.6	107
313	Eosinophils from Physiology to Disease: A Comprehensive Review. <i>BioMed Research International</i> , 2018 , 2018, 9095275	3	95
312	Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies. <i>PLoS Medicine</i> , 2014 , 11, e1001718	11.6	89
311	Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1811-5	7	87
310	Cerebrospinal fluid S-adenosylmethionine (SAME) and glutathione concentrations in HIV infection: effect of parenteral treatment with SAME. <i>Neurology</i> , 1995 , 45, 1678-83	6.5	80
309	The incidence of AIDS-defining illnesses at a current CD4 count \geq 200 cells/ μ L in the post-combination antiretroviral therapy era. <i>Clinical Infectious Diseases</i> , 2013 , 57, 1038-47	11.6	79
308	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , 2010 , 376, 340-5 ⁴⁰		77
307	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018 , 66, 893-903	11.6	75
306	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e253-e261	14.2	75

305	Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 3253-9	5.9	74
304	Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients. <i>HIV Medicine</i> , 2010 , 11, 104-13	2.7	73
303	Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study. <i>PLoS ONE</i> , 2020 , 15, e0239570	3.7	69
302	Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2020 , 22, 91-94	2.8	66
301	Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. <i>Aids</i> , 2009 , 23, 455-60	3.5	63
300	Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. <i>Lancet HIV</i> , 2015 , 2, e464-73	7.8	60
299	Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013 , 13, 471	4	58
298	Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. <i>New England Journal of Medicine</i> , 2020 , 382, 1232-1243	59.2	56
297	Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. <i>European Journal of Epidemiology</i> , 2012 , 27, 657-65	12.1	56
296	B-cell subset alterations and correlated factors in HIV-1 infection. <i>Aids</i> , 2013 , 27, 1209-17	3.5	56
295	Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. <i>Aids</i> , 2012 , 26, 1917-26	3.5	56
294	Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1163-1171	5.1	56
293	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , 2015 , 20,	19.8	55
292	Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. <i>Clinical Infectious Diseases</i> , 2010 , 50, 1316-21	11.6	53
291	COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6366-6378	15.9	53
290	Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. <i>Aids</i> , 2011 , 25, 2249-58	3.5	50
289	Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 425-33	5.1	48
288	The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development. <i>Drugs</i> , 2005 , 65, 879-904	12.1	48

287	Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. <i>HIV Medicine</i> , 2005 , 6, 145-50	2.7	48
286	Risk of developing specific AIDS-defining illnesses in patients coinfecting with HIV and hepatitis C virus with or without liver cirrhosis. <i>Clinical Infectious Diseases</i> , 2009 , 49, 612-22	11.6	47
285	Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. <i>HIV Medicine</i> , 2004 , 5, 437-47	2.7	46
284	Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. <i>HIV Medicine</i> , 2004 , 5, 334-43	2.7	43
283	Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. <i>Aids</i> , 2003 , 17, 1993-5	3.5	40
282	Ganciclovir therapy for cytomegalovirus (CMV) infection of the central nervous system in AIDS patients: monitoring by CMV DNA detection in cerebrospinal fluid. <i>Journal of Infectious Diseases</i> , 1995 , 171, 1603-6	7	39
281	Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. <i>Antiviral Therapy</i> , 2011 , 16, 1103-12	1.6	38
280	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 759-65	1.9	38
279	Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. <i>Aids</i> , 2010 , 24, 924-8	3.5	38
278	Polymerase chain reaction for <i>Toxoplasma gondii</i> DNA in the cerebrospinal fluid of AIDS patients with focal brain lesions. <i>Aids</i> , 1994 , 8, 1691-4	3.5	38
277	Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. <i>Aids</i> , 2015 , 29, 1205-15	3.5	37
276	A comparison of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients. <i>Journal of Neurology</i> , 1997 , 244, 35-9	5.5	37
275	Role of brain biopsy in the management of focal brain lesions in HIV-infected patients. Gruppo Italiano Cooperativo AIDS & Tumori. <i>Neurology</i> , 2000 , 54, 993-7	6.5	36
274	Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. <i>Archives of Internal Medicine</i> , 2010 , 170, 410-9		35
273	Use of polymerase chain reaction assays of aqueous humor in the differential diagnosis of retinitis in patients infected with human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , 1997 , 24, 1100-6	11.6	35
272	Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , 2017 , 18, 171-180	2.7	33
271	Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord. <i>Aids</i> , 2014 , 28, 2297-306	3.5	33
270	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases</i> , 2012 , 12, 119-27	25.5	33

269	Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. <i>European Journal of Endocrinology</i> , 2007 , 156, 503-9	6.5	33
268	Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy. <i>Journal of Neurology</i> , 1999 , 246, 723-5	5.5	33
267	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 71, 263-71	3.1	33
266	Infection-related and -unrelated malignancies, HIV and the aging population. <i>HIV Medicine</i> , 2016 , 17, 590-600	2.7	31
265	Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. <i>Annals of Internal Medicine</i> , 2017 , 166, 9-17	8	30
264	A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial. <i>Antiviral Therapy</i> , 2005 , 10, 735-743	1.6	30
263	Etravirine for the treatment of HIV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2008 , 6, 427-33	5.5	29
262	Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHT study. <i>Lancet HIV</i> , 2020 , 7, e740-e751	7.8	29
261	Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2372-8	5.1	28
260	Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. <i>Journal of Infectious Diseases</i> , 2003 , 188, 1827-33	7	28
259	Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. <i>PLoS ONE</i> , 2014 , 9, e87160	3.7	28
258	Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. <i>HIV Medicine</i> , 2019 , 20 Suppl 1, 3-11	2.7	27
257	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Clinical Microbiology and Infection</i> , 2016 , 22, 288.e1-8	9.5	27
256	Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals. <i>Aids</i> , 2014 , 28, 1351-6	3.5	27
255	In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2525-32	5.1	27
254	Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1800-9	11.6	26
253	Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. <i>HIV Medicine</i> , 2011 , 12, 4-13	2.7	26
252	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 213-7	5.1	26

251	Reversal of CSF positivity for JC virus genome by cidofovir in a patient with systemic lupus erythematosus and progressive multifocal leukoencephalopathy. <i>Neurological Sciences</i> , 2001 , 22, 17-20	3.5	26
250	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the IcoNA cohort. <i>Journal of the International AIDS Society</i> , 2019 , 22, e25227	5.4	24
249	Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. <i>PLoS ONE</i> , 2012 , 7, e41673	3.7	24
248	Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. <i>International Journal of Cancer</i> , 2012 , 130, 2990-6	7.5	24
247	Antiretroviral therapy in geriatric HIV patients: the GEPP0 cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2879-2886	5.1	23
246	Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naïve HIV-infected patients presenting with tuberculosis as AIDS-defining condition. <i>Clinical Infectious Diseases</i> , 2012 , 54, 853-61	11.6	23
245	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. <i>PLoS ONE</i> , 2017 , 12, e0173893	3.7	23
244	LC-MS/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 169, 11-18	3.5	21
243	Biobanking for COVID-19 research. <i>Panminerva Medica</i> , 2020 ,	2	21
242	Stranger Months: How SARS-CoV-2, Fear of Contagion, and Lockdown Measures Impacted Attendance and Clinical Activity During February and March 2020 at an Urban Emergency Department in Milan. <i>Disaster Medicine and Public Health Preparedness</i> , 2020 , 1-10	2.8	21
241	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2055-2059	5.1	20
240	Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 56, 790-2	5.1	20
239	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1955-1964	5.1	20
238	Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the IcoNA Foundation study. <i>BMC Infectious Diseases</i> , 2014 , 14, 79	4	19
237	Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy. <i>HIV Medicine</i> , 2013 , 14, 153-60	2.7	19
236	Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results. <i>Aids</i> , 2014 , 28, 2269-79	3.5	19
235	The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*. <i>HIV Medicine</i> , 2012 , 13, 62-72	2.7	19
234	Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. <i>PLoS ONE</i> , 2017 , 12, e0186549	3.7	18

233	Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up. <i>Clinical Microbiology and Infection</i> , 2013 , 19, E542-4	9.5	18
232	Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, e113-5	3.1	18
231	Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. <i>Clinical Microbiology and Infection</i> , 2011 , 17, 928-34	9.5	18
230	Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 177-182	5.1	18
229	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. <i>Frontiers in Immunology</i> , 2021 , 12, 675678	8.4	18
228	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1363-1367	5.1	17
227	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1056-62	5.1	17
226	Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfecting patients. <i>PLoS ONE</i> , 2013 , 8, e64283	3.7	17
225	Clinical and immunological aspects of HIV infection in drug addicts. <i>Clinical Immunology and Immunopathology</i> , 1989 , 50, S166-76		17
224	Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. <i>Scientific Reports</i> , 2020 , 10, 21291	4.9	16
223	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. <i>BMC Medicine</i> , 2018 , 16, 79	11.4	16
222	Bictegravir. <i>Current Opinion in HIV and AIDS</i> , 2018 , 13, 326-333	4.2	16
221	Estimating minimum adult HIV prevalence: a cross-sectional study to assess the characteristics of people living with HIV in Italy. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 282-7	1.6	16
220	Inconsistent condom use among HIV-positive women in the "Treatment as Prevention Era": data from the Italian DIDI study. <i>Journal of the International AIDS Society</i> , 2013 , 16, 18591	5.4	16
219	Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. <i>Aids</i> , 2007 , 21, 1648-51	3.5	16
218	Mediator release in cerebrospinal fluid of human immunodeficiency virus-positive patients with central nervous system involvement. <i>Journal of Neuroimmunology</i> , 1992 , 38, 155-61	3.5	16
217	Pulmonary Vascular Thrombosis in COVID-19 Pneumonia. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021 , 35, 3631-3641	2.1	16
216	Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2039-2046	5.1	15

215	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 83, 240-250	3.1	15
214	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 735-41	5.1	15
213	Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. <i>Aids</i> , 2014 , 28, 2407-15	3.5	15
212	Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients. <i>HIV Medicine</i> , 2011 , 12, 109-17	2.7	15
211	Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 831-6	5.1	15
210	Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure. <i>AIDS Research and Human Retroviruses</i> , 2003 , 19, 1151-3	1.6	15
209	Oligoclonal IgG bands in cerebrospinal fluid and serum during asymptomatic human immunodeficiency virus infection. <i>Annals of Neurology</i> , 1988 , 24, 277-9	9.4	15
208	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1245-1253	11.6	15
207	Infections after Allogeneic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1179-1188	4.7	14
206	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. <i>PLoS ONE</i> , 2017 , 12, e0177402	3.7	14
205	Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study. <i>Lancet HIV</i> , 2015 , 2, e540-9	7.8	14
204	Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease. <i>Aids</i> , 2013 , 27, 2335-44	3.5	14
203	Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 1224-7	5.1	14
202	Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010 , 15, 165-75	1.6	14
201	Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion. <i>Journal of Leukocyte Biology</i> , 2007 , 82, 1212-20	6.5	14
200	Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1949-1954	5.1	14
199	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. <i>BMC Public Health</i> , 2018 , 18, 870	4.1	13
198	HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. <i>Journal of Medical Virology</i> , 2008 , 80, 201-8	19.7	13

197	Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males. <i>PLoS ONE</i> , 2017 , 12, e0186367	3.7	12
196	Longitudinal evaluation of occult hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption. <i>Infection</i> , 2011 , 39, 121-6	5.8	12
195	Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, e51-4	3.1	12
194	First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006). <i>Infection</i> , 2007 , 35, 134-42	5.8	12
193	Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. <i>European Journal of Clinical Pharmacology</i> , 2005 , 61, 545-9	2.8	12
192	Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, 294-9	3.1	12
191	Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105893	14.3	11
190	Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. <i>Aids</i> , 2017 , 31, 835-846	3.5	11
189	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2869-2878	5.1	11
188	Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63, 339-45	3.1	11
187	Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens. <i>Aids</i> , 2012 , 26, 1837-40	3.5	11
186	Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients. <i>Aids</i> , 2003 , 17, 2669-71	3.5	11
185	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019 , 20, 99-109	2.7	11
184	Cardiovascular disease in women with HIV-1 infection. <i>International Journal of Cardiology</i> , 2017 , 241, 50-56	3.2	10
183	HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 103.e7-103.e10	9.5	10
182	Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. <i>Journal of Infection</i> , 2016 , 73, 619-623	18.9	10
181	Darunavir for the treatment of HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1149-1163	4	10
180	Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. <i>HIV Medicine</i> , 2017 , 18, 33-44	2.7	10

179	Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy. <i>Journal of the International AIDS Society</i> , 2015 , 18, 20037	5.4	10
178	Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs. <i>Liver International</i> , 2013 , 33, 1113-20	7.9	10
177	Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. <i>Therapeutics and Clinical Risk Management</i> , 2014 , 10, 9-15	2.9	10
176	Incidence of deep venous thrombosis in COVID-19 hospitalized patients during the first peak of the Italian outbreak. <i>Phlebology</i> , 2021 , 36, 375-383	2	10
175	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018 , 19, 475	2.7	10
174	The NIQ of Lopinavir is Predictive of a 48-Week Virological Response in Highly Treatment-Experienced HIV-1-Infected Subjects Treated with a Lopinavir/Ritonavir-Containing Regimen. <i>Antiviral Therapy</i> , 2004 , 9, 537-543	1.6	10
173	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA $\geq 10^4$ cp/mL. <i>Infection</i> , 2017 , 45, 521-528	5.8	9
172	Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study. <i>HIV Medicine</i> , 2015 , 16, 533-43	2.7	9
171	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2663-9	5.1	9
170	Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy. <i>Antiviral Therapy</i> , 2012 , 17, 447-58	1.6	9
169	Immune recovery and T cell subset analysis during effective treatment with maraviroc. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2474-8	5.1	9
168	Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2007 , 101, 339-44	3.1	9
167	Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations. <i>Journal of Medical Virology</i> , 2008 , 80, 937-41	19.7	9
166	Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir. <i>Journal of Medical Virology</i> , 2006 , 78, 1537-41	19.7	9
165	Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection. <i>Aids</i> , 2004 , 18, 121-3	3.5	9
164	Relation between CD4 cell counts and HIV RNA levels at onset of opportunistic infections. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 27, 44-8	3.1	9
163	Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. <i>PLoS ONE</i> , 2017 , 12, e0171611	3.7	9
162	HIV and tuberculosis: The paradox of dual illnesses and the challenges of their fighting in the history. <i>Tuberculosis</i> , 2020 , 122, 101921	2.6	9

161	Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. <i>International Journal of Antimicrobial Agents</i> , 2018 , 52, 492-499	14.3	9
160	In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2547-2553	5.1	8
159	Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study. <i>PLoS ONE</i> , 2017 , 12, e0184128	3.7	8
158	The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. <i>HIV Medicine</i> , 2018 , 19, 90-101	2.7	8
157	Polyclonal serum-free light chains elevation in HIV-infected patients. <i>Aids</i> , 2012 , 26, 2107-10	3.5	8
156	Relation Between CD4 Cell Counts and HIV RNA Levels at Onset of Opportunistic Infections. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001 , 27, 44-48	3.1	8
155	Schistosomiasis, strongyloidiasis and Chagas disease: the leading imported neglected tropical diseases in Italy. <i>Journal of Travel Medicine</i> , 2020 , 27,	12.9	8
154	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab278	1	8
153	Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. <i>Aids</i> , 2019 , 33, 1256-1260	3.5	8
152	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 267.e1-267.e4	9.5	7
151	Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. <i>HIV Medicine</i> , 2019 , 20, 264-273	2.7	7
150	Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2016 , 17, 471-8	2.7	7
149	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 632-633	5.1	7
148	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , 2015 , 10, e0140877	3.7	7
147	Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy. <i>Infection</i> , 2009 , 37, 270-82	5.8	7
146	Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1932-4	5.1	7
145	Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 50, 192-5	3.1	7
144	The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 447-52	3.1	7

143	Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2004 , 72, 181-6	19.7	7
142	Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy. <i>Lancet, The</i> , 1991 , 337, 1488	4.0	7
141	Kappa light chain predominance in serum and cerebrospinal fluid from human immunodeficiency virus type 1 (HIV-1)-infected patients. <i>Journal of Neuroimmunology</i> , 1991 , 32, 259-68	3.5	7
140	Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?. <i>HIV Medicine</i> , 2018 , 19, 42-48	2.7	7
139	Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients. <i>PLoS ONE</i> , 2017 , 12, e0182007	3.7	7
138	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 3460-3470	5.1	7
137	Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. <i>BMC Infectious Diseases</i> , 2017 , 17, 43	4	6
136	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1224-1228	3.4	6
135	The use of circulating cathodic antigen rapid test and serology for diagnosis of active <i>Schistosoma mansoni</i> infection in migrants in Italy, a non-endemic country: a cross sectional study. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2017 , 112, 452-455	2.6	6
134	Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens. <i>Journal of Medical Virology</i> , 2019 , 91, 1937-1943	19.7	6
133	Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. <i>BMC Nephrology</i> , 2014 , 15, 51	2.7	6
132	Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. <i>Antiviral Research</i> , 2014 , 108, 44-7	10.8	6
131	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3085-94	5.1	6
130	Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. <i>Journal of Infectious Diseases</i> , 2013 , 207, 759-67	7	6
129	HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme. <i>International Journal of STD and AIDS</i> , 2010 , 21, 224-5	1.4	6
128	Magnitude and determinants of CD4 recovery after HAART resumption after 1 cycle of treatment interruption. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 52, 588-94	3.1	6
127	Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 384-7	5.1	6
126	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. <i>Clinical Infectious Diseases</i> , 2021 , 73, 50-59	11.6	6

125	Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: A post-hoc analysis of a prospective cohort study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2156-2164	4.5	6
124	Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 812-815	5.1	6
123	Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofy324	1	6
122	Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 79, 617-623	3.1	6
121	An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. <i>New Microbiologica</i> , 2015 , 38, 443-90	1.1	6
120	Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.. <i>New England Journal of Medicine</i> , 2022 , 386, 1793-1803	59.2	6
119	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts 5 log10 copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2732-2741	5.1	5
118	Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106027	14.3	5
117	Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2). <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1332-1337	5.1	5
116	Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment. <i>HIV Medicine</i> , 2020 , 21, 599-606	2.7	5
115	Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. <i>HIV Medicine</i> , 2018 , 19, 102-117	2.7	5
114	Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir. <i>Medicine (United States)</i> , 2016 , 95, e3780	1.8	5
113	Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients. <i>Medicine (United States)</i> , 2016 , 95, e4144	1.8	5
112	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1637-42	5.1	5
111	Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPPPO" Cohort. <i>PLoS ONE</i> , 2019 , 14, e0222225	3.7	5
110	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , 2015 , 10, e0124252	3.7	5
109	Raltegravir in treatment naive patients. <i>European Journal of Medical Research</i> , 2009 , 14 Suppl 3, 22-9	4.8	5
108	Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 1055-64	5.1	5

107	Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients. <i>Aids</i> , 2004 , 18, 2205-8	3.5	5
106	Thallium-201 single photon emission computed tomography in the management of contrast-enhancing brain lesions in a patient with AIDS. <i>Clinical Infectious Diseases</i> , 1996 , 23, 185-6	11.6	5
105	T and B cell responses to cytomegalovirus antigens in healthy blood donors and bone marrow transplant recipients. <i>FEMS Immunology and Medical Microbiology</i> , 1993 , 7, 55-62		5
104	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2323-e2333	11.6	5
103	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 628-639	5.1	5
102	Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. <i>Viruses</i> , 2020 , 12,	6.2	5
101	Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. <i>Aids</i> , 2021 , 35, 1061-1072	3.5	5
100	Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study. <i>Drug Design, Development and Therapy</i> , 2016 , 10, 1589-603	4.4	5
99	Brief Report: Outcome of Acute Hepatitis B Virus Infection in HIV-1-Infected Patients: Possible Factors Associated With Resolution or Chronicity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 82, 175-180	3.1	5
98	Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106252	14.3	5
97	Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. <i>HIV Clinical Trials</i> , 2018 , 19, 52-60		4
96	Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression. <i>Medicine (United States)</i> , 2016 , 95, e5222	1.8	4
95	Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1436-9	5.1	4
94	A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. <i>Infection</i> , 2014 , 42, 757-62	5.8	4
93	Optimal dietary calcium intake in HIV treated patients: no femoral osteoporosis but higher cardiovascular risk. <i>Clinical Nutrition</i> , 2014 , 33, 363-6	5.9	4
92	Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19806	5.4	4
91	Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 1243-50	1.6	4
90	Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2960-3	5.1	4

89	Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. <i>BMC Infectious Diseases</i> , 2011 , 11, 23	4	4
88	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial. <i>Journal of Clinical Virology</i> , 2010 , 47, 253-74.5	4.5	4
87	Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 179-84	3.1	4
86	Monotherapy with atazanavir as a simplification strategy: results from an observational study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, e101-3	3.1	4
85	Immunological basis for IgE hyper-production in enfuvirtide-treated HIV- positive patients. <i>Journal of Clinical Immunology</i> , 2006 , 26, 168-76	5.7	4
84	Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen. <i>AIDS Research and Human Retroviruses</i> , 2005 , 21, 545-54	1.6	4
83	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. <i>PLoS ONE</i> , 2016 , 11, e0160761	3.7	4
82	Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression. <i>Patient</i> , 2020 , 13, 375-387	3.7	4
81	Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients. <i>Antiviral Therapy</i> , 2019 , 24, 69-72	1.6	4
80	Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 88, 132-137	3.1	4
79	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. <i>BMC Public Health</i> , 2019 , 19, 1291	4.1	3
78	Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. <i>Antiviral Therapy</i> , 2019 , 24, 321-331	1.6	3
77	An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study. <i>Infectious Diseases</i> , 2018 , 50, 220-222	3.1	3
76	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1352-60	5.1	3
75	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 75, 465-471	3.1	3
74	Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients. <i>BMC Infectious Diseases</i> , 2017 , 17, 723	4	3
73	Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 1341-4	5.1	3
72	Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. <i>Infection</i> , 2007 , 35, 451-6	5.8	3

71	Diagnosis of virus-associated opportunistic diseases of the central nervous system in patients with HIV infection by polymerase chain reaction on cerebrospinal fluid. <i>Annals of the New York Academy of Sciences</i> , 1994 , 724, 170-2	6.5	3
70	Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load. <i>PLoS ONE</i> , 2018 , 13, e0191300	3.7	3
69	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. <i>AIDS Reviews</i> , 2017 , 19,	1.5	3
68	Role of blood pressure dysregulation on kidney and mortality outcomes in COVID-19. Kidney, blood pressure and mortality in SARS-CoV-2 infection. <i>Journal of Nephrology</i> , 2021 , 34, 305-314	4.8	3
67	Rhodococcus defluvii pneumonia: first reported case in humans. <i>Aids</i> , 2019 , 33, 2261-2263	3.5	3
66	Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. <i>Aids</i> , 2018 , 32, 205-215	3.5	3
65	Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation. <i>Journal of the International AIDS Society</i> , 2018 , 21, e25200	5.4	3
64	Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection. <i>New Microbiologica</i> , 2021 , 44, 135-144	1.1	3
63	Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019 , 38, 1857-1865	5.3	2
62	Pharmacotherapeutic management of HIV in transplant patients. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1235-1250	4	2
61	Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians. <i>BMC Infectious Diseases</i> , 2017 , 17, 734	4	2
60	Evolving treatment implementation among HIV-infected pregnant women and their partners: results from a national surveillance study in Italy, 2001-2015. <i>Journal of Global Health</i> , 2017 , 7, 010407	4.3	2
59	Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. <i>HIV Medicine</i> , 2018 , 19, 324-338	2.7	2
58	Immune activation, inflammation and HIV DNA after 96 weeks of ATV/r monotherapy: a MODAt substudy. <i>Antiviral Therapy</i> , 2018 , 23, 633-637	1.6	2
57	High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort. <i>Medicine (United States)</i> , 2016 , 95, e4434	1.8	2
56	Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study. <i>Medicine (United States)</i> , 2016 , 95, e5020	1.8	2
55	Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort. <i>HIV Medicine</i> , 2015 , 16, 412-20	2.7	2
54	Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 67, 258-67	3.1	2

53	Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. <i>Cancer</i> , 2013 , 119, 2710-9	6.4	2
52	Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome. <i>Aids</i> , 2004 , 18, 821-3	3.5	2
51	Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 681-689	5.1	2
50	Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen. <i>Aids</i> , 2021 , 35, 1513-1516	3.5	2
49	A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 477-479	4.4	2
48	Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 82, 373-376	3.7	2
47	Stepping up HIV-1 low-level viraemia surveillance in South Africa. <i>Lancet Infectious Diseases</i> , 2018 , 18, 130-131	25.5	2
46	Viral antibodies in serum and cryoprecipitate of patients with essential mixed and secondary cryoglobulinemia. Preliminary results. <i>Research in Clinic and Laboratory</i> , 1986 , 16, 345-8		2
45	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authorsLresponse. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1549-1550 ¹	5.1	1
44	Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study). <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2700-2702	5.1	1
43	Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 84, e24-e28	3.1	1
42	Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. <i>HIV Medicine</i> , 2018 , 19, 252-260	2.7	1
41	Brief Report: Drop in CD4+ Counts Below 200 Cells/ μ l After Reaching (or Starting From) Values Higher than 350 Cells/ μ l in HIV-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 76, 417-422	3.1	1
40	The association between detected drug resistance mutations and CD4 T-cell decline in HIV-positive individuals maintained on a failing treatment regimen. <i>Antiviral Therapy</i> , 2018 , 23, 105-116	1.6	1
39	Immortal time bias: authorsLreply. <i>Aids</i> , 2015 , 29, 860-1	3.5	1
38	Predictors of lack of serological response to syphilis treatment in HIV-infected subjects. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19654	5.4	1
37	An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19771	5.4	1
36	Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19811	5.4	1

35	Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, e34-5	3.1	1
34	No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2011 , 83, 391-8	19.7	1
33	Cross-sectional and retrospective questionnaire-trial to evaluate exercise habits in a sample of HIV-infected individuals with type 2 diabetes mellitus. <i>Sport Sciences for Health</i> , 2005 , 1, 81-90	1.3	1
32	Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance.. <i>Sexually Transmitted Infections</i> , 2022 ,	2.8	1
31	Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofac029	1	1
30	Levels of Alpha-Fetoprotein and Association with Mortality in Hepatocellular Carcinoma of HIV-1-Infected Patients.. <i>Journal of Oncology</i> , 2022 , 2022, 3586064	4.5	1
29	548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S340-S340	1	1
28	Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study). <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1646-1648	5.1	1
27	Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression. <i>Aids</i> , 2019 , 33, 1987-1994	3.5	1
26	Achieving virological control in pan-resistant HIV-1 infection: A case series.. <i>EBioMedicine</i> , 2022 , 77, 103908	3.8	1
25	Dolutegravir: a new option for HIV treatment. <i>Future Virology</i> , 2014 , 9, 801-810	2.4	0
24	Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity. <i>Aids</i> , 2007 , 21, 2366-7	3.5	0
23	Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy.. <i>Drug Design, Development and Therapy</i> , 2022 , 16, 297-304	4.4	0
22	Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV.. <i>PLoS ONE</i> , 2022 , 17, e0262917	3.7	0
21	Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects.. <i>Pharmacological Research</i> , 2022 , 176, 106064	10.2	0
20	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , 2020 , 15, e0243625	3.7	0
19	Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance. <i>Aids</i> , 2020 , 34, 2152-2155	3.5	0
18	Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. <i>BMC Infectious Diseases</i> , 2021 , 21, 557	4	0

17	HIV-DNA undetectability during chronic HIV infection: frequency and predictive factors. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2994-2997	5.1
16	Switching antiretrovirals in older patients. <i>Lancet HIV,the</i> , 2019 , 6, e640-e641	7.8
15	Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis. <i>BMC Health Services Research</i> , 2012 , 12, 38	2.9
14	Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authorsLreply. <i>Aids</i> , 2015 , 29, 857-9	3.5
13	Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine. <i>Aids</i> , 2013 , 27, 2661-3	3.5
12	HIV protease inhibitors: present and future. <i>Future Virology</i> , 2011 , 6, 571-580	2.4
11	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mLAuthorsLresponse. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2541-2542	5.1
10	In Vivo Treatment with Fusion Inhibitor Enfuvirtide Leads to Increased IL-12 Production by Autologous in Vitro Activated Monocytes from HIV-infected Individuals. <i>Journal of Antivirals & Antiretrovirals</i> , 2009 , 01, 043-050	2
9	Long-term response in patients receiving HAART including nelfinavir: experience from two Italian centers. <i>Journal of Chemotherapy</i> , 2002 , 14, 189-93	2.3
8	505. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S354-S355	1
7	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. <i>PLoS ONE</i> , 2016 , 11, e0156360	3.7
6	Changes in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Index in Treated HIV-1 Infected People on Virological Suppression Who Switched to a Different Antiretroviral Regimen. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 87, e169-e173	3.1
5	Two-drug regimens with dolutegravir for maintaining viral suppression: looking at the right companion. <i>Aids</i> , 2019 , 33, 2264-2266	3.5
4	Exercise ECG for coronary artery disease screening in people living with HIV. <i>Aids</i> , 2021 , 35, 933-938	3.5
3	Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA-matching barrier. <i>Transplant Infectious Disease</i> , 2021 , 23, e13551	2.7
2	Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness. <i>New Microbiologica</i> , 2014 , 37, 285-306	1.1
1	Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection.. <i>PLoS ONE</i> , 2022 , 17, e0265348	3.7